В. В. Бредер

Research interests

Publications

• Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

  The Lancet · 2025 · 10.1016/s0140-6736(24)02551-0

• Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

  Journal of Hepatology · 2025 · 10.1016/j.jhep.2025.03.033

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

  Annals of Oncology · 2024 · 10.1016/j.annonc.2024.02.005

• Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

  ˜The œLancet. Gastroenterology & hepatology · 2024 · 10.1016/s2468-1253(24)00095-5

• Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2024 · https://doi.org/10.1016/s1470-2045(24)00082-2

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

  The Lancet Oncology · 2023 · 10.1016/s1470-2045(23)00469-2

• Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(22)00326-6

• Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

  Journal of Clinical Oncology · 2022 · 10.1200/jco.2022.40.4_suppl.379

• Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2100070

• Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

  JAMA Oncology · 2021 · 10.1001/jamaoncol.2021.2301

• Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(21)00151-0

• IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).

  Journal of Clinical Oncology · 2021 · 10.1200/jco.2021.39.3_suppl.267

• Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

  JAMA Oncology · 2021 · 10.1001/jamaoncol.2021.3523

• Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

  Journal of Hepatology · 2021 · https://doi.org/10.1016/j.jhep.2021.11.030

• Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1915745

• Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.2019.37.15_suppl.4004

• IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz446.002

• Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01307

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)32453-9

Current projects

No projects listed.